BioSpace News Archive

As Minister of Health, protecting the health and safety of Canadians is my top priority. I am deeply concerned by recent reports of serious issues Canadians have been facing with implanted medical devices.

Aziyo Biologics, Inc., announced that it has received U.S. Food and Drug Administration (FDA) clearance of the CanGaroo Envelope device for use with implantable neurostimulator devices.

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today changes to its Board of Directors

Nu Skin Enterprises, Inc. announced it will hold an investor day event at its corporate headquarters in Provo, Utah, on Thursday, Feb. 28, 2019.

Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. (“Halozyme” or the “Company”) (NASDAQ: HALO).

ForeverGreen Worldwide Corporation announced today financial results for the third quarter ended Sept. 30, 2018

Q-State Biosciences, Inc. (“Q-State”) today announced it has closed its Series A financing and has joined with Minneapolis-based Pairnomix, LLC (“Pairnomix”) to create the world-leading precision medicine company focused on rare and devastating central nervous system (CNS) diseases.

Advancements in laser technologies over the years have contributed to various applications of cosmetic treatments, contributing to the growth of the global photorejuvenation equipment market.

TriLink BioTechnologies, a Maravai LifeSciences company and a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that the company’s CleanTag® Small RNA Library Prep Kit was the enabling technology in a new study of next-generation sequencing of small RNAs from single cells.

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib (HMPL-012 or sulfatinib) and fruquintinib in combination with checkpoint inhibitors.